BRAF inhibitor combined with EGFR inhibitor for PDXs model of<em>BRAF</em>mutant recurrent and metastatic colorectal cancer

王　英; 马　晗; 李文涛

doi:10.19401/j.cnki.1007-3639.2017.07.003

您当前的位置：

首页 >

文章列表页 >

BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer

更新时间：2025-12-31

- BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer
- China Oncology Vol. 27, Issue 7, Pages: 533-537(2017)
- 作者机构：
  
  复旦大学附属肿瘤医院介入治疗科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.07.003
  CLC：
- Published Online：16 August 2017，
  
  Published：16 August 2017
- 稿件说明：
移动端阅览
王　英,马　晗,李文涛,等 . BRAF和EGFR抑制剂联合用于

王　英, 马　晗, 李文涛. BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer[J]. China Oncology, 2017, 27(7): 533-537.
王　英,马　晗,李文涛,等 . BRAF和EGFR抑制剂联合用于 DOI： 10.19401/j.cnki.1007-3639.2017.07.003.

王　英, 马　晗, 李文涛. BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer[J]. China Oncology, 2017, 27(7): 533-537. DOI： 10.19401/j.cnki.1007-3639.2017.07.003.

摘要

背景与目的：结直肠癌患者中BRAF基因突变的概率为5%~15%，临床预后明显差于无突变者。该研究将BRAF与表皮生长因子受体(epidermal growth factor receptor，EGFR)抑制剂联合用于BRAF V600E突变型复发转移性结直肠癌的患者来源异种移植(patient-derived xenografts，PDXs)模型，观察其安全性、可行性及疗效。方法：2016年1月—2016年12月，复旦大学附属肿瘤医院34例疑似结直肠癌术后复发或转移的患者利用CT引导下的穿刺活检方法获取组织标本，建立复发转移性结直肠癌的PDXs模型，筛选BRAF突变者传代培养至F2代进行药物实验，实验组分为BRAF抑制剂组(A组)、EGFR抑制剂组(B组)、BRAF和EGFR抑制剂联合组(C组)及安慰剂对照组(D组)。给药3周后处死实验动物，统计建模成功率及抑瘤率。结果：34例患者中共23例病理证实为结直肠癌复发或转移，成功建立16个PDX模型，建模成功率为69.6%(16/23)。共筛选出4例BRAF V600E基因突变者，成功建立4个BRAF突变型复发转移性结直肠癌的PDXs模型。实验组无明显药物毒性相关性死亡，实验组抑瘤率分别为21.57%、21.61%和66.81%，差异有统计学意义(P0.05)。结论：CT引导下的穿刺活检建立复发转移性结直肠癌的PDXs模型成功率高，针对EGFR和BRAF的双重打击治疗安全、可行，能够明显提高BRAF突变型结直肠癌的疗效。

Abstract

Background and purpose: The incidence of BRAF mutation ranged from 5% to 15% among colorectal cancer according to previous studies

and was associated with poor survival. To evaluate safety

feasibilityand efficiency of BRAF inhibitor combined with epidermal growth factor receptor (EGFR) inhibitor for patient-derived xenografts (PDXs) of BRAF mutant recurrent and metastatic colorectal cancer. Methods: From Jan. 2016 to Dec. 2016

a total of 34 colorectal cancer patients were performed CT guided biopsy because of recurrence or metastasis indicated by image examination. PDXs models of recurrent and metastatic colorectal cancer were established by biopsy specimen. Screened the BRAF V600E mutant and cultivated to F2 generation for drug administration. The experimental group: BRAF inhibitor (Group A)

EGFR inhibitor (Group B)

BRAF and EGFR inhibitor (Group C). The control group: placebo (Group D). After three weeks

the efficiency was evaluated by tumor inhibition rate. Results: Twenty-three of the patients were confirmed recurrence or metastasis by pathology. Sixteen PDXs models were established

with success rate of 69.6% (16/23). Four BRAF V600E mutant patients were screened and PDXs models were established. There was no obvious drug toxicity related death in experimental group. The tumor inhibition rate of experimental group was 21.57%、21.61% and 66.81%

respectively. Group C had the most significant reduction of tumor volume (P0.05). Conclusion: Combination of BRAF and EGFR inhibitor had high safety

feasibility and efficiency in PDXs of BRAF mutant recurrent and metastatic colorectal cancer.

关键词

Keywords

references

Views

2364

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanisms underlying tepoxalin-mediated regulation of cell growth and chemoresistance via ABCB1 in colorectal cancer

Research progress and prospects of exercise intervention in comprehensive management of colorectal cancer

Artificial intelligence-based assessment of surgical skills in laparoscopic right hemicolectomy for colon cancer

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Zhijun HE

Liwen JIN

Related Institution

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Oncology, Shanghai Pudong New District Zhoupu Hospital

Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Gastroenterology, Shanghai Pudong New District Zhoupu Hospital

AI问答

⁰

BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer

DOI：10.19401/j.cnki.1007-3639.2017.07.003

摘要

Abstract

关键词

Keywords

references